OBJECTIVES: evaluation of comparative cost-effectiveness of treatment of CAP complicated by sepsis with moxifloxacin compared to ceftriaxone + azithromycin in adult patients. METHODS: literature search revealed prospective non-randomized comparative controlled clinical trial (n=87) where treatment efficacy of CAP complicated by sepsis was evaluated. MOX group received moxifloxacin (400 mg i.v.) 3-4 days with further switch to 400 mg per os daily. CEAZ group received combined therapy with ceftriaxone 2000 mg i.v. and azithromycin 5000 mg during 5 days. Efficacy criteria were length of antibacterial treatment, ICU and in-hospital days. Cost-effectiveness analysis was performed. RESULTS: Patients of MOX group spent 2.7±1.3 ICU days compared to 3.9±1.4 days (p<0.05) in CEAZ group. Antimicrobial treatment took 7.0±0.4 days in MOX and 10.0±0.5 days in CEAZ group (p<0.05).  There was not statistically significant deference in hospital days. Costs of antibacterial treatment and ICU stay were 17,803 RUR (€447) per patient in MOX group and 19,020 (€478) in CEAZ group. CONCLUSIONS: treatment of CAP complicated by sepsis with moxifloxacin compared to combined therapy in adult patients leads to ICU stay reduction by 1.2 days and cost saving by 1216 RUB (€31).